Publications

Home Research Publications

Publications

We’re proud to share the publications that have emerged from ChadTough Defeat DIPG-funded research. Each study represents a step forward in understanding DIPG/DMG, improving treatments, and offering hope to families facing this devastating diagnosis.

A road map for the treatment of pediatric diffuse midline glioma

Purine salvage promotes treatment resistance in H3K27M-mutant diffuse midline glioma

PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma

Targeting Diffuse Midline Glioma with a novel anti-CD99 Antibody

An ERK5-PFKFB3 axis regulates glycolysis and represents a therapeutic vulnerability in pediatric diffuse midline glioma

DNA methylation landscapes in DIPG reveal methylome variability that can be modified pharmacologically

Understanding and therapeutically exploiting cGAS/STING signaling in glioblastoma

Mechanisms of telomere maintenance and associated therapeutic vulnerabilities in malignant gliomas

Sequential intravenous and intracerebroventricular GD2-CAR T-cell therapy for H3K27M-mutated diffuse midline gliomas

Immunotherapy-related cognitive impairment after CAR T cell therapy in mice

Cholinergic Neuronal Activity Promotes Diffuse Midline Glioma Growth through Muscarinic Signaling

The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models

Therapeutic targeting of differentiation-state dependent metabolic vulnerabilities in diffuse midline glioma

Targeting DNA Repair and Survival Signaling in Diffuse Intrinsic Pontine Gliomas to Prevent Tumor Recurrence

The rise of TIM‐3: A promising immune target in diffuse midline gliomas

Combination of locoregional radiotherapy with a TIM-3 aptamer improves survival in diffuse midline glioma models

Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201

GABA production induced by imipridones is a targetable and imageable metabolic alteration in diffuse midline gliomas

Rational combination platform trial design for children and young adults with diffuse midline glioma: A report from PNOC

A review of current therapeutics targeting the mitochondrial protease ClpP in diffuse midline glioma, H3 K27-altered

Liquid biopsy in H3K27M diffuse midline glioma

Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors

CHD2 Regulates Neuron–Glioma Interactions in Pediatric Glioma

Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas

Spatial 3D genome organization controls the activity of bivalent chromatin during human neurogenesis

Protocol for live-cell imaging of immune synapse formation and activation of CAR T cells against cancer cells

EZHIP’s role in diffuse midline glioma: echoes of oncohistones?

Progress Toward Epigenetic Targeted Therapies for Childhood Cancer

Lactylation fuels nucleotide biosynthesis and facilitates deuterium metabolic imaging of tumor proliferation in H3K27M-mutant gliomas

Just a spoonful of metformin helps the medicine go down

Exploiting the gut microbiome for brain tumour treatment

Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways

Glioma synapses recruit mechanisms of adaptive plasticity

Targeting SWI/SNF ATPases in H3.3K27M diffuse intrinsic pontine gliomas

ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma

Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma

TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory

Therapeutic avenues for targeting treatment challenges of diffuse midline gliomas

Cancer neuroscience: State of the field, emerging directions

Neuronal-Activity Dependent Mechanisms of Small Cell Lung Cancer Progression

Tumor inflammation-associated neurotoxicity

Ataxia-telangiectasia mutated (Atm) disruption sensitizes spatially-directed H3.3K27M/TP53 diffuse midline gliomas to radiation therapy

CAR T cell therapies for diffuse midline glioma

Efficacy of convection enhanced delivery of MTX110 (soluble panobinostat) in preclinical Diffuse Intrinsic Pontine Glioma models using metabolic hyperpolarized 13C imaging

Common molecular features of H3K27M DMGs and PFA ependymomas map to hindbrain developmental pathways

Clinical, genomic, and epigenomic analyses of H3K27M-mutant diffuse midline glioma long-term survivors reveal a distinct group of tumors with MAPK pathway alterations

Histone H3 K27M-mediated regulation of cancer cell stemness and differentiation in diffuse midline glioma

BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma

PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation

VRK1 as a synthetic lethal target in VRK2 promoter–methylated cancers of the nervous system

Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma

GABAergic neuron-to-glioma synapses in diffuse midline gliomas

Oncohistone interactome profiling uncovers contrasting oncogenic mechanisms and identifies potential therapeutic targets in high grade glioma

Structural variants shape driver combinations and outcomes in pediatric high-grade glioma

A druggable addiction to de novo pyrimidine biosynthesis in diffuse midline glioma

Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome

Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas

Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma

Receptor tyrosine kinase (RTK) targeting in pediatric high-grade glioma and diffuse midline glioma: Pre-clinical models and precision medicine

GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas

Upfront Biology-Guided Therapy in Diffuse Intrinsic Pontine Glioma: Therapeutic, Molecular, and Biomarker Outcomes from PNOC003

Generation of immunocompetent syngeneic allograft mouse models for pediatric diffuse midline glioma

Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma

Epigenetically defined therapeutic targeting in H3G34R/V high-grade gliomas

Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma

Brain stem gliomas and current landscape

Transcriptomic Analysis of Diffuse Intrinsic Pontine Glioma (DIPG) Identifies a Targetable ALDH-Positive Subset of Highly Tumorigenic Cancer Stem-like Cells

Epigenetic activation of a RAS/MYC axis in H3.3K27M-driven cancer

Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas

MR Imaging Correlates for Molecular and Mutational Analyses in Children with Diffuse Intrinsic Pontine Glioma

Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG

Histone Variant and Cell Context Determine H3K27M Reprogramming of the Enhancer Landscape and Oncogenic State

Diffuse Intrinsic Pontine Glioma: From Diagnosis to Next-Generation Clinical Trials

Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening

Donate to Fund DIPG Research & Support

Your support today means more tomorrows for kids diagnosed with DIPG and DMG.

$60 $125 $250 $500 Donate

You Can Help

There are countless ways to get involved and support our mission to Defeat DIPG.

1-on-1 Support

Connect with one of our DIPG/DMG nurses who can help you navigate this disease.

Stay connected with ChadTough Defeat DIPG

In each newsletter, we share the reasons we fight, the progress we’ve made, and how you can help. Subscribe today to join us in the fight to Defeat DIPG.

"*" indicates required fields

ChadTough Defeat DIPG Foundation is a 501(c)(3) nonprofit organization. 
P.O. Box 907, Saline, MI 48176 | (734) 707-8732 
Federal Tax ID: 47-4041494

© 2024 ChadTough Defeat DIPG Foundation | Privacy Policy

charity-navigator-badge

platinum-transparency-badge